Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 10363968.
- Also identified by PMC identifier 2249691.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To study the induction of anti-"self" CD8+ T-cell reactivity against the tumor antigen gp100, we used a mouse transgenic for a chimeric HLA-A*0201/H-2 Kb molecule (A2/Kb). We immunized the mice with a recombinant vaccinia virus encoding a form of gp100 that had been modified at position 210 (from a threonine to a methionine) to increase epitope binding to the restricting class I molecule. Immunogens containing the "anchor-fixed" modification elicited anti-self CD8+ T cells specific for the wild-type gp100(209-217) peptide pulsed onto target cells. More important, these cells specifically recognized the naturally presented epitope on the surface of an A2/Kb-expressing murine melanoma, B16. These data indicate that anchor-fixing epitopes could enhance the function of recombinant virus-based immunogens.
Medical subject headings
- Autoimmunity
- CD8-Positive T-Lymphocytes
- Cancer Vaccines
- HLA-A Antigens
- Melanoma, Experimental
- Membrane Glycoproteins
- Neoplasm Proteins
- Peptide Fragments
- Transfection